Lupin completes acquisition of VISUfarma

02 Apr 2026 Evaluate

Lupin has completed acquisition of VISUfarma B.V. (VISUfarma), a leading European specialty pharmaceutical company focused on ophthalmology, from GHO Capital Partners LLP (GHO). The acquisition represents a significant milestone in Lupin’s strategy to expand its specialty care portfolio and strengthen its presence in Europe.

The integration of VISUfarma has significantly expanded Lupin’s ophthalmology portfolio to over 60 branded products spanning dry eye, glaucoma, eyelid hygiene, blepharitis, retinal health, and specialty nutraceuticals. VISUfarma’s strong commercial footprint across key European markets, including Italy, the UK, Spain, Germany, and France, is strengthened by a highly experienced team with deep ophthalmology expertise, trusted relationships, and strong local market insight.

VISUfarma enhances Lupin’s ability to address the growing global demand for innovative eye care solutions, driven by an ageing population and the growing burden of diabetes-related eye complications.

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

Lupin Share Price

2302.40 8.85 (0.39%)
09-Apr-2026 13:19 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1718.40
Dr. Reddys Lab 1211.30
Cipla 1226.60
Zydus Lifesciences 904.95
Lupin 2302.40
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×